HACKENSACK, N.J., Dec. 9, 2021 /PRNewswire/ -- Researchers from Hackensack Meridian Health John Theurer Cancer Center (JTCC), a part of the Georgetown Lombardi Comprehensive Cancer Center, will present updates on treatment advances in multiple myeloma, lymphoma, leukemia, and bone marrow transplantation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held virtually and live at the Georgia World Congress Center in Atlanta from December 11-14, 2021.
"John Theurer Cancer Center is a world leader in the care of people with hematologic malignancies and a pioneer in clinical research related to blood cancers. The acceptance of 47 studies from our investigators demonstrates our expertise in this area and our commitment to improving outcomes not only for our own patients, but people affected by these diseases everywhere," said Andre Goy, MD, MS, chairman and executive director of the John Theurer Cancer Center.
This year's presentations will include a plenary session as the #2 ranked abstract for the entire conference with data that will change the paradigm in the treatment of relapsed aggressive lymphoma for the FIRST TIME in 40 years. Dr. Lori Leslie, MD, director of the Indolent Lymphoma and Chronic Lymphocytic Leukemia Research Programs at JTCC will be co-presenter of the phase III international ZUMA-7 clinical trial (abstract #2), which compared axicabtagene ciloleucel (axi-cel) CAR T-cell therapy with standard of care (SOC) in patients with relapsed / refractory diffuse large B-cell lymphoma (DLBCL) after initial therapy. For decades the SOC has been high dose therapy followed by autologous stem cell transplant (ASCT) – but patients with high risk disease and / or early relapse still do very poorly. Axi-cel is now used to treat DLBCL that have failed two prior regimens of treatment, including standard salvage chemoimmunotherapy (CIT) followed by ASCT.
Bringing axi-cel earlier as second line therapy resulted in a 2.5-fold increase in median event-free survival (defined as the time without any cancer progression or any related complications) and doubled the complete response rate (65% vs 32%).
"This study is the first to change the paradigm for relapsed and refractory DLBCL that was established decades ago, demonstrating significant and clinically meaningful improvements in outcome," said Dr. Leslie. "Axi-cel may replace chemoimmunotherapy and autologous stem cell transplantation as the standard of care for people with DLBCL that relapses or persists after initial treatment. It is a game-changer."
The JTCC presentations address new developments in the treatment of multiple myeloma, lymphoma, leukemia, and bone marrow transplantation, as well as a study assessing gene therapy for sickle cell disease in pediatric patients.
Multiple Myeloma Research
Lymphoma Research
Leukemia Research
Bone Marrow Transplantation Research
Sickle Cell Disease Research
The full set of ASH data presentations by JTCC researchers is as follows:
Abstract # | Type | Title | Authors | Presenting (PST) |
2 | Plenary Scientific Session | Lori A. Leslie | Sunday, December 12, 2021: 2:00 PM-4:00 PM | |
7 | Oral | Stacey Rifkin | Saturday, December 11, 2021: 9:30 AM-11:00 AM | |
50 | Oral | A Large Multicenter Real-World Evidence (RWE) Analysis of Autoimmune (AI) Diseases and Lymphoma: Histologic Associations, Disease Characteristics, Survival, and Prognostication | Tatyana A. Feldman, Jason Lofters | Saturday, December 11, 2021: 9:45 AM |
66 | Oral | James K McCloskey | Saturday, December 11, 2021: 10:45 AM | |
93 | Oral | Pashna N. Munshi, Lori A. Leslie, | Saturday, December 11, 2021: 10:00 AM | |
133 | Oral | Tatyana A. Feldman, Lori A. Leslie | Saturday, December 11, 2021: 12:00 PM-1:30 PM | |
165 | Oral | Andrew Ip, MD, Andre Goy | Saturday, December 11, 2021: 12:30 PM | |
184 | Oral | A Multi-Center Retrospective Review of COVID-19 Outcomes in Patients with Lymphoid Malignancy | Lori A. Leslie | Saturday, December 11, 2021: 12:00 PM-1:30 PM |
307 | Oral | James K McCloskey | Saturday, December 11, 2021: 4:00 PM-5:30 PM | |
395 | Oral | Lori A. Leslie | Sunday, December 12, 2021: 10:30 AM | |
548 | Oral | David S. Siegel | Sunday, December 12, 2021: 4:30 PM-6:00 PM | |
561 | Oral | Polyclonality Strongly Correlates with Biological Outcomes and Is Significantly Increased Following Improvements to the Phase 1/2 HGB-206 Protocol and Manufacturing of LentiGlobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy (GT) | Stacey Rifkin-Zenenberg | Sunday, December 12, 2021: 4:30 PM-6:00 PM |
622 | Oral |
| Feldman | Monday, December 13, 2021: 11:15 AM |
623 | Oral | Tatyana A. Feldman | Monday, December 13, 2021: 11:30 AM | |
651 | Oral | David S. Siegel | Monday, December 13, 2021: 11:00 AM | |
691 | Oral | James McCloskey | Monday, December 13, 2021: 2:45 PM | |
744 | Oral | Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium | Andre H. Goy | Monday, December 13, 2021: 2:45 PM-4:15 PM
|
755 | Oral | Stacey Rifkin | Monday, December 13, 2021: 3:45 PM | |
1202 | Poster 1 | Andre H. Goy | Saturday, December 11, 2021, 5:30 PM-7:30 PM | |
1273 | Poster 1 | James K McCloskey
| Saturday, December 11, 2021: 5:30 PM-7:30 PM | |
1276 | Poster 1 | James K McCloskey | Saturday, December 11, 2021, 5:30 PM-7:30 PM | |
1347 | Poster I | Production of Anti-Spike Antibodies in Response to COVID Vaccine in Lymphoma Patients | Alexandra Della Pia, Michael Koropsak, Lori A. Leslie,, Andre H. Goy, Tatyana A. Feldman, and Andrew Ip | Saturday, December 11, 2021, 5:30 PM-7:30 PM |
1365 | Poster I | Tatyana A. Feldman | Saturday, December 11, 2021: 5:30 PM-7:30 PM | |
1428 | Poster I | Samuel Singer | Saturday, December 11, 2021, 5:30 PM-7:30 PM | |
1651 | Poster 1 | Noa Biran | Saturday, December 11, 2021, 5:30 PM-7:30 PM | |
1764 | Poster I | Andre H. Goy | Saturday, December 11, 2021, 5:30 PM-7:30 PM | |
1828 | Poster I | Maher Albitar, Andrew L. Pecora, Andrew Ip, Andre H. Goy, Jeffrey Justin Estella, Sukhdeep Kaur, Hyung C. Suh,, Michele L. Donato and Scott D. Rowley | Saturday, December 11, 2021, 5:30 PM-7:30 PM | |
2395 | Poster II | Maher Albitar, Andre H. Goy | Sunday, December 12, 2021, 6:00 PM-8:00 PM | |
2423 | Poster II | Tatyana A. Feldman | Sunday, December 12, 2021: 6:00 PM-8:00 PM | |
2448 | Poster II | Tatyana A. Feldman | Sunday, December 12, 2021: 6:00 PM-8:00 PM | |
2454 | Poster II | Tatyana A. Feldman | Sunday, December 12, 2021, 6:00 PM-8:00 PM | |
2465 | Poster II | Jennifer Krajewski | Sunday, December 12, 2021, 6:00 PM-8:00 PM | |
2495 | Poster II | Andrew Ip | Sunday, December 12, 2021, 6:00 PM-8:00 PM | |
2695 | Poster II | David H. Vesole | Sunday, December 12, 2021, 6:00 PM-8:00 PM | |
2748 | Poster II | Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma | Noa Biran | Sunday, December 12, 2021: 6:00 PM-8:00 PM |
2751 | Poster II | Noa Biran | Sunday, December 12, 2021: 6:00 PM-8:00 PM | |
2757 | Poster II | David S. Siegel | Sunday, December 12, 2021: 6:00 PM-8:00 PM | |
2832 | Poster II | Andre H. Goy | Sunday, December 12, 2021: 6:00 PM-8:00 PM | |
2892 | Poster II | Sunday, December 12, 2021, 6:00 PM-8:00 PM | ||
2900 | Poster II | Assessment of Serology after Sars-Cov-2 Vaccine in Allogeneic HCT Recipients | Melissa Baker, Maria Cortes, Michele L. Donato, Sukhdeep Kaur, Hyung C. Suh, Alison Morawski, Phyllis McKiernan, Amy Einstein, Michele Boonstra, and Scott D. Rowley | Sunday, December 12, 2021, 6:00 PM-8:00 PM |
2996 | Poster II | Kimberley Doucette, ,David H. Vesole, Catherine Lai | Sunday, December 12, 2021: 6:00 PM-8:00 PM | |
3463 | Poster III | Maher Albitar, Andrew Ip, Andre H. Goy, Jamie Koprivnikar and James K McCloskey | Monday, December 13, 2021: 6:00 PM-8:00 PM | |
3534 | Poster III | Noa Biran | Monday, December 13, 2021, 6:00 PM-8:00 PM | |
3574 | Poster III | Tatyana A. Feldman | Monday, December 13, 2021: 6:00 PM-8:00 PM | |
3682 | Poster III | James K McCloskey | Monday, December 13, 2021, 6:00 PM-8:00 PM | |
3826 | Poster III | Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium | Andre H. Goy | Monday, December 13, 2021, 6:00 PM-8:00 PM |
4115 | Poster III | Andre H. Goy | Monday, December 13, 2021, 6:00 PM-8:00 PM |
For more information about the 63rd ASH Annual Meeting and Exposition or the research being presented, please visit: hematology.org/meetings/annual-meeting.
About John Theurer Cancer Center at Hackensack University Medical Center
John Theurer Cancer Center at Hackensack University Medical Center is New Jersey's best cancer center, as recognized by U.S. News & World Report. As a premier cancer center in the State we are also the largest and most comprehensive center dedicated to diagnosis, treatment, management, research, screening, and preventive care as well as survivorship of patients with all types of cancers. The 16 specialized divisions covering the complete spectrum of cancer care have developed a close-knit team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. Each year, more people in the New Jersey/New York metropolitan area turn to John Theurer Cancer Center for cancer care than to any other facility in New Jersey. John Theurer Cancer Center is part of the Georgetown Lombardi Comprehensive Cancer Center, an NCI designated comprehensive cancer center. Housed within a 775-bed not-for-profit teaching, tertiary care, and research hospital, John Theurer Cancer Center provides state-of-the-art technological advances, compassionate care, research innovations, medical expertise, and a full range of aftercare services that distinguish John Theurer Cancer Center from other facilities. For additional information, please visit www.jtcancercenter.org.
SOURCE Hackensack Meridian Health